Peter J. Neumann

Recommendations for Conduct, Methodological Practices, and Reporting of Cost-effectiveness Analyses

Gillian D Sanders, Peter J. Neumann, Anirban Basu et al. · JAMA · 2016 · 3K citations · Full text

Pharmacy, Health Administration, Health Policy +17

Updating Cost-Effectiveness — The Curious Resilience of the $50,000-per-QALY Threshold

Peter J. Neumann, Joshua T. Cohen, Milton C. Weinstein · New England Journal of Medicine · 2014 · 2.3K citations

Pharmacy, Health Policy, Pharmacoeconomics +17

Using Real-World Data for Coverage and Payment Decisions: The ISPOR Real-World Data Task Force Report

Louis P. Garrison, Peter J. Neumann, Pennifer Erickson et al. · Value in Health · 2007 · 705 citations

Business, Economics, Public Finance +13

Evidence of SARS-CoV-2 Infection in Returning Travelers from Wuhan, China

Sebastian Hoehl, Holger F. Rabenau, Annemarie Berger et al. · New England Journal of Medicine · 2020 · 623 citations · Full text

Veterinary Medicine, Infectious Disease Control, Infectious Diseases +15

Key principles for the improved conduct of health technology assessments for resource allocation decisions

Michael Drummond, J. Sanford Schwartz, Bengt Jönsson et al. · International Journal of Technology Assessment in Health Care · 2008 · 492 citations

Public Affairs, Health Administration, Health Policy +16